- Home
- CRBU vs ANTA Comparison
CRBU vs ANTA Comparison
Compare CRBU & ANTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRBU | ANTA |
|---|---|---|
| Founded | 2011 | 2022 |
| Country | United States | Singapore |
| Employees | N/A | 113 |
| Industry | Medicinal Chemicals and Botanical Products | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.4M | 182.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRBU | ANTA |
|---|---|---|
| Price | $2.38 | $7.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $10.75 | ★ $16.17 |
| AVG Volume (30 Days) | ★ 1.6M | 1.6K |
| Earning Date | 05-08-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.63 | $21.95 |
| Revenue Next Year | $10.93 | $30.46 |
| P/E Ratio | ★ N/A | $19.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.96 | $6.25 |
| 52 Week High | $3.53 | $15.65 |
Technical Indicators
Market Signals| Indicator | CRBU | ANTA |
|---|---|---|
| Relative Strength Index (RSI) | 67.29 | 39.74 |
| Support Level | $1.75 | $6.80 |
| Resistance Level | $2.97 | $9.81 |
| Average True Range (ATR) | 0.17 | 0.41 |
| MACD | 0.03 | -0.15 |
| Stochastic Oscillator | 90.48 | 0.00 |
Price Performance
Historical ComparisonAbout CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
About ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to institutional and corporate customers in the crypto asset industry. The company operates through Antalpha Prime platform in the following areas: Supply chain financing and Technology and services. Its revenue prominently consists of technology financing fees charged on the supply chain loans.